Interpace Biosciences Announces Record Second Quarter 2024 Financial and Business Results

PARSIPPANY, NJ, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG) today announced financial results for the second quarter ended June 30, 2024 and provided a business and financial update.

globenewswire.com

Interpace Diagnostics® Announces Undefined Extension of Medicare Coverage for PancraGEN®, a Molecular Diagnostic Test That Assesses Cancer Risk of Pancreatic Cysts

PARSIPPANY, NJ, July 29, 2024 (GLOBE NEWSWIRE) -- Interpace Diagnostics®, a subsidiary of Interpace Biosciences®, (“Interpace” or the “Company”) (OTCQX: IDXG) today responded to the undefined extension granted by Centers for Medicare & Medicaid Services (CMS) to Novitas, its Medicare Administrative Contractor (MAC).

globenewswire.com

Interpace Biosciences Announces First Quarter 2024 Financial and Business Results

PARSIPPANY, NJ, May 09, 2024 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG) today announced financial results for the first quarter ended March 31, 2024 and provided a business and financial update.

globenewswire.com

Interpace Biosciences Announces Preliminary Full-year and Fourth Quarter 2023 Financial and Business Results

PARSIPPANY, NJ, March 07, 2024 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG) today announced financial results for the fourth quarter and full year ending December 31, 2023.

globenewswire.com

Interpace Biosciences Announces Record Third Quarter 2023 Financial and Business Results

PARSIPPANY, NJ, Nov. 08, 2023 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG) today announced financial results for the third quarter ended September 30, 2023 and provided a business and financial update.

globenewswire.com

Interpace Biosciences Announces Record Second Quarter 2023 Financial and Business Results

PARSIPPANY, NJ, Aug. 09, 2023 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG) today announced financial results for the second quarter ended June 30, 2023 and provided a business and financial update.

globenewswire.com

Interpace Biosciences Releases Preliminary Record Second Quarter 2023 Business Results; Updates Status of PancraGEN® Reimbursement

PARSIPPANY, NJ, July 10, 2023 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG) today announced preliminary business results for the second quarter ending June 30, 2023, and provided an update on recent activities. Final Q2 financial results are expected to be released no later than August 11, 2023.

globenewswire.com

Interpace Biosciences Announces New $7.5 Million Credit Facility with Comerica Bank

PARSIPPANY, NJ, Oct. 15, 2021 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG) today announced that it, along with its subsidiaries, has entered into a new $7.5 Million revolving credit facility with Comerica Bank (the “Bank”). The facility matures on September 30, 2023 and allows for advances based on 80% of eligible accounts receivable plus an applicable non-formula amount consisting of $2,000,000 of additional availability at close, stepping down $250,000 per quarter beginning with the quarter ending June 30, 2022. The interest rate is equal to prime plus .50%, prime being the greater of the bank's stated prime rate or the sum of the daily adjusting LIBOR rate, plus 2.5% per annum. The Bank will have a first priority security interest in substantially all of Interpace's and its subsidiaries' assets and will be senior to the existing $7.5 Million bridge loans made by the Company's private equity investors.

globenewswire.com

Interpace Biosciences, Inc. (IDXG) Reports Q2 Loss, Tops Revenue Estimates

Interpace Biosciences, Inc. (IDXG) delivered earnings and revenue surprises of -72.92% and 0.50%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

zacks.com

Interpace Biosciences, Inc. (IDXG) Is a Great Choice for "Trend" Investors, Here's Why

Interpace Biosciences, Inc. (IDXG) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.

zacks.com

Interpace Biosciences Announces First Quarter 2021 Financial and Business Results

PARSIPPANY, NJ, May 11, 2021 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG) today announced financial results for the fiscal quarter ended March 31, 2021 and provided a business and financial update.

globenewswire.com

Interpace Biosciences Raises Full Year 2021 Revenue Guidance

Parsippany, NJ, April 19, 2021 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG) today announced an update to its full year 2021 revenue guidance originally provided on March 31, 2021.

globenewswire.com

Interpace Pharma Solutions Announces New Advanced Offering in RNA Biomarker Analysis

Parsippany, NJ, April 12, 2021 (GLOBE NEWSWIRE) -- Interpace Pharma Solutions, a subsidiary of Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG) announced today new capability in advancing RNA biomarker analysis for gene and cell-based therapies.

globenewswire.com

Interpace Biosciences Announces New PLA Code and Medicare Reimbursement Increase for Proprietary Thyroid Assay, ThyGeNEXT®

Parsippany, NJ, April 05, 2021 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG) announced today that Novitas, its Medicare Administrative Contractor, has agreed to recognize the new Proprietary Laboratory Analysis (PLA) code that specifically identifies ThyGeNEXT® as a distinct test from any other test or service. PLA codes are an addition to the current procedural terminology (CPT®) code set approved by the American Medical Association CPT® Editorial Panel. PLA codes are alpha-numeric CPT codes with a corresponding descriptor for labs that want to more specifically identify their test. The new PLA code for ThyGeNEXT® is 0245U and the reimbursement for this code remains $2,919, representing a significant price increase over the prior reimbursement level of $560. In December, 2020, Novitas issued a new local coverage determination (LCD) for ThyGeNEXT® that reflects the test's enhanced mutation panel. In 2020, Interpace processed approximately 15,000 ThyGeNEXT® tests for over 700 physicians.

globenewswire.com

Interpace Biosciences Announces Full Year and Fourth Quarter 2020 Financial and Business Results

PARSIPPANY, NJ, March 31, 2021 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG) today announced financial results for the fiscal quarter ended December 31, 2020 and provided a business and financial update.

globenewswire.com

Interpace Biosciences Announces Divestiture of New Haven CLIA lab to DiamiR

Part of Company's Site Consolidation and Cost Savings Measures

globenewswire.com

Interpace Biosciences Announces Contract for Thyroid Testing with Blue Cross Blue Shield of Illinois

In-network status for ThyGeNEXT® and ThyraMIR® with State's Largest Payer

globenewswire.com

Interpace Biosciences Announces Acceptance for Trading on the OTCQX

PARSIPPANY, NJ, Feb. 24, 2021 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (OTCQX: IDXG) (“Interpace Biosciences” or the “Company”), an emerging leader in enabling personalized medicine, today announced that on February 24, 2021, the Company satisfied the requirements for trading of the Company's common stock on the OTCQX® Best Market (“OTCQX”) and will begin trading on OTCQX at the open of the market on February 25, 2021 under the symbol IDXG. The Company previously traded on Nasdaq.

globenewswire.com

Interpace Biosciences Announces Path Forward in Letter to Shareholders

PARSIPPANY, NJ, Feb. 16, 2021 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (NASDAQ: IDXG) (“Interpace”), a leader in enabling personalized medicine, issued the following communication to shareholders:

globenewswire.com

Interpace Biosciences Announces CFO Leadership Transition

PARSIPPANY, NJ, Feb. 04, 2021 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (NASDAQ: IDXG) (“Interpace”) a leader in enabling personalized medicine, announced today that its Board of Directors has appointed Tom Freeburg, Chief Accounting Officer, as Interpace's Chief Financial Officer (“CFO”). Mr. Freeburg succeeds Fred Knechtel effective February 1, 2021.

globenewswire.com

Interpace Biosciences Announces License Agreement with Rutgers University and Mass General Hospital

Parsippany, NJ, Feb. 01, 2021 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (Nasdaq: IDXG) announced today that it has executed a license agreement with Rutgers, The State University of New Jersey, and Massachusetts General Hospital for a novel monoclonal antibody platform, Das-1, used in the risk assessment of pancreatic cysts. Although some cysts may have no cancerous potential at all, other cysts carry up to a 48 percent chance of harboring invasive cancer, and surgery to remove them is often complex. Therefore, there is a need to develop additional tools to identify which pancreatic cysts may develop into cancer and which ones will not. In a recent, national multicenter study of patients undergoing surgery for pancreatic cysts, the Das-1 antibody was able to accurately identify pancreatic cysts likely to become cancerous with high sensitivity and high specificity in comparison to current clinical guidelines (Das, K et al, “Cross Validation of the Monoclonal Antibody Das-1 in Identification of High-Risk Mucinous Pancreatic Cystic Lesion”, (Gastroenterology 2019; 157:720-730). Das-1 is gaining recognition among experts in the GI community as evidenced by its inclusion as a component in the Pancreatic Cyst Biomarker Alliance sponsored in part by the National Cancer Institute.

globenewswire.com

Interpace Biosciences Announces Contract for Thyroid Testing with Blue Cross Blue Shield of Florida

In-network status for ThyGeNEXT® and ThyraMIR® with State's Largest Payer

globenewswire.com

Interpace Biosciences to Host Third Quarter 2020 Financial Results Conference Call on Thursday, January 21, 2021

PARSIPPANY, NJ, Jan. 20, 2021 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (NASDAQ: IDXG) announced today that it will hold its third quarter 2020 financial results conference call and webcast after the close of market on Thursday, January 21, 2021 at 4:30 p.m. ET.

globenewswire.com

Interpace Biosciences Announces Third Quarter 2020 Financial and Business Results and Completion of $5 Million Bridge Loan

Conference Call and Webcast Thursday January 21, 2021 at 4:30 pm ET

globenewswire.com

Interpace Biosciences Announces Executive Transition: Jack Stover to Retire as President and Chief Executive Officer Thomas Burnell Appointed as Successor

Parsippany, NJ, Nov. 25, 2020 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (NASDAQ: IDXG) today announced that Jack Stover, President & Chief Executive Officer, will retire effective December 31, 2020. He will be replaced as President and Chief Executive Officer by Thomas Burnell, PhD., effective December 1, 2020. Mr. Stover, who will step down from the Interpace Board of Directors once Dr. Burnell joins the company and is appointed to the Board, will serve as an advisor to the company through the middle of 2021 in order to support the transition.

globenewswire.com

Interpace Biosciences Receives Nasdaq Deficiency Notice Due to Delayed Filing of Form 10-Q; No Immediate Impact on Listing

PARSIPPANY, NJ, Nov. 19, 2020 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (“Interpace” or the “Company”) (NASDAQ: IDXG) on November 18, 2020 received notice from the Listing Qualifications Staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, due to the delay in the filing of the Company's Form 10-Q for the quarterly period ended September 30, 2020 (the “Form 10-Q”) with the Securities and Exchange Commission (the “SEC”), Interpace does not currently satisfy Nasdaq Listing Rule 5250(c)(1), which requires the timely filing of all periodic reports with the SEC. The deficiency has no immediate effect on the listing or trading of the Company's common stock on Nasdaq.

globenewswire.com

Interpace Biosciences (NASDAQ:IDXG) Shares Gap Up to $2.98

Interpace Biosciences, Inc. (NASDAQ:IDXG) shares gapped up prior to trading on Wednesday . The stock had previously closed at $2.98, but opened at $3.56. Interpace Biosciences shares last traded at $4.09, with a volume of 572,556 shares. Several research firms recently issued reports on IDXG. Zacks Investment Research cut shares of Interpace Biosciences from a […]

thelincolnianonline.com

Brokerages Anticipate Interpace Diagnostics Group Inc (NASDAQ:IDXG) to Post -$1.64 Earnings Per Share

Wall Street analysts forecast that Interpace Diagnostics Group Inc (NASDAQ:IDXG) will post earnings of ($1.64) per share for the current quarter, according to Zacks. Two analysts have issued estimates for Interpace Diagnostics Group’s earnings. The highest EPS estimate is ($1.56) and the lowest is ($1.72). Interpace Diagnostics Group posted earnings per share of ($1.10) in […]

thelincolnianonline.com

Next Generation Cancer Diagnostics: Technologies and Global Markets (2019-2025) - ResearchAndMarkets.com

The

businesswire.com

The Daily Biotech Pulse: Gilead's Filgotinib Stumbles With FDA, J&J Laps Up Momenta In $6.5B Deal, 2 IPOs

Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 18) Avenue Therapeutics Inc (NASDAQ: ATXI) Checkmate Pharmaceuticals Inc (NASDAQ: CMPI) DarioHealth Corp (NASDAQ:...

benzinga.com

Clovis Rubraca Data, And Other News: The Good, Bad And Ugly Of Biopharma

Clovis reports positive data from TRITON clinical trial. Interpace Biosciences sinks on potential compliance roadblocks.

seekingalpha.com

$5.6 Billion Worldwide Veterinary Reference Laboratory Industry to 2025 - Featuring GD Animal Health, Boehringer Ingelheim & Zoetis Among Others - ResearchAndMarkets.com

The

businesswire.com

Luminex Corp (DE) (LMNX) Q2 2020 Earnings Call Transcript | The Motley Fool

LMNX earnings call for the period ending June 30, 2020.

fool.com

QIAGEN Reports Full Results for Second Quarter and First Half Of 2020

QIAGEN reports full results for second quarter and first half of 2020

businesswire.com

Clostridium Diagnostics - Global Market Analysis and Outlook 2020-2027: Revised with COVID-19 Growth Deviations - ResearchAndMarkets.com

The

businesswire.com

Insights on the Malaria Diagnostics Global Market to 2027 - Featuring Leica Microsystems, Nikon & Olympus Among Others - ResearchAndMarkets.com

The

businesswire.com

Interpace Diagnostics Group (NASDAQ:IDXG) Cut to “Buy” at ValuEngine

Interpace Diagnostics Group (NASDAQ:IDXG) was downgraded by stock analysts at ValuEngine from a “strong-buy” rating to a “buy” rating in a research note issued on Friday, ValuEngine reports. A number of other equities analysts have also commented on the stock. Maxim Group reaffirmed a “buy” rating and issued a $12.00 price objective on shares of […]

thelincolnianonline.com

U.S. shares higher at close of trade; Dow Jones Industrial Average up 0.36%

U.S. shares higher at close of trade; Dow Jones Industrial Average up 0.36%

uk.investing.com

Interpace Biosciences, Inc. (IDXG) CEO Jack Stover on Q1 2020 Results - Earnings Call Transcript

Interpace Biosciences, Inc. (NASDAQ:IDXG) Q1 2020 Earnings Conference Call June 25, 2020 04:30 PM ET Company Participants Jack Stover - President and CEO Fred K

seekingalpha.com

Cancer Genetics Reports First Quarter 2020 Financial Results and Provides Strategic Business Updates | MarketScreener

marketscreener.com

Comparing Interpace Diagnostics Group (NASDAQ:IDXG) & Utah Medical Products (NASDAQ:UTMD)

Utah Medical Products (NASDAQ:UTMD) and Interpace Diagnostics Group (NASDAQ:IDXG) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their dividends, risk, earnings, profitability, valuation, analyst recommendations and institutional ownership. Analyst Ratings This is a breakdown of recent recommendations and price targets for […]

thelincolnianonline.com

Interpace Diagnostics Group (NASDAQ:IDXG) Stock Rating Upgraded by ValuEngine

Interpace Diagnostics Group (NASDAQ:IDXG) was upgraded by research analysts at ValuEngine from a “buy” rating to a “strong-buy” rating in a research report issued on Wednesday, ValuEngine reports. Several other analysts have also commented on the stock. HC Wainwright lowered their price objective on shares of Interpace Diagnostics Group from $15.00 to $12.00 and set […]

thelincolnianonline.com

Global Molecular Diagnostics Market (2020 to 2024) - Insights & Forecast with Potential Impact of COVID-19 - ResearchAndMarkets.com

The

businesswire.com

Zacks: Brokerages Anticipate Interpace Diagnostics Group Inc (NASDAQ:IDXG) Will Announce Earnings of -$1.19 Per Share

Equities analysts expect Interpace Diagnostics Group Inc (NASDAQ:IDXG) to announce earnings of ($1.19) per share for the current fiscal quarter, Zacks Investment Research reports. Two analysts have made estimates for Interpace Diagnostics Group’s earnings. The highest EPS estimate is ($1.02) and the lowest is ($1.36). Interpace Diagnostics Group reported earnings of ($1.00) per share in […]

thelincolnianonline.com

Global Molecular Diagnostics Partnering Terms and Agreements 2014 - 2020 - ResearchAndMarkets.com

The

businesswire.com

Molecular Diagnostics of Infectious Disease 2020-2024: Strategic Situation Analysis and Impact of COVID-19 - ResearchAndMarkets.com

The

businesswire.com

Competing in the 2020 Global Enteric Disease Testing Market: Supplier Shares, Segment Forecasts for 10 Assays, Growth Opportunities for Suppliers - ResearchAndMarkets.com

The

businesswire.com

Global Market Trajectory & Analytics for the World Molecular Diagnostics Market: Rising Emphasis on Lab Automation to Augur Well for Market Growth - ResearchAndMarkets.com

The "Molecular Diagnostics - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering. Amid the COVID-19 crisis...

marketwatch.com

Competing in the 2020 Global Respiratory Disease Testing Market: Supplier Shares, Segment Forecasts for 9 Assays, Growth Opportunities for Suppliers - ResearchAndMarkets.com

The

businesswire.com

Global Personalized Medicine Market 2020: Assessment of the Latest Concepts for Pharmacogenomics, Pharmacogenetics, Pharmacoproteomics and Metabolomics - ResearchAndMarkets.com

The

businesswire.com

Global Animal Biotechnology Industry Assessment 2018-2028 - Molecular Diagnostics in Animals, Biotechnology-based Veterinary Medicine, Regulatory Issues, Companies Involved - ResearchAndMarkets.com

The

businesswire.com

Molecular Diagnostics Market By Key Players, Deployment Type, Applications, Vertical, and Region – Forecast 2026

May 11, 2020 (AmericaNewsHour) -- Global Molecular Diagnostics Market is valued approximately at USD 8.4 billion in 2019 and is anticipated to grow with a...

marketwatch.com

ARK Genomic Revolution Multi-Sector ETF: An Overbought But Promising Niche Play

I am neutral on ARKG, an exciting, niche biotech ETF that currently looks overbought on the charts. I expect investor interest in this space to stay elevated on

seekingalpha.com

Veterinary Reference Laboratory (VRL) Market 2020 | COVID -19 Research Report- IDEXX Laboratories, Inc., VCA, Inc., GD Animal Health, Greencross Ltd

May 05, 2020 Xherald -- Veterinary Reference Laboratory (VRL) Market report will make detailed analysis mainly on in-depth research on the development...

marketwatch.com

Maxim Group Reaffirms Their Hold Rating on Vertex Pharmaceuticals (VRTX)

Maxim Group analyst Jason McCarthy maintained a Hold rating on Vertex Pharmaceuticals (VRTX) today. The company's shares closed last Thursday at $251.20.

smarteranalyst.com

H.C. Wainwright Keeps a Buy Rating on CareDx (CDNA)

In a report released today, Yi Chen from H.C. Wainwright reiterated a Buy rating on CareDx (CDNA), with a price target of $40.00. The company's shares

smarteranalyst.com

Analysts' Top Healthcare Picks: Alimera (ALIM), Seattle Genetics (SGEN)

There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Alimera (ALIM) and Seattle Genetics (SGEN) with bullish

smarteranalyst.com

Immutep (IMMP) Receives a Buy from Maxim Group

In a report released today, Jason McCarthy from Maxim Group assigned a Buy rating to Immutep (IMMP), with a price target of $2.00. The company's shares

smarteranalyst.com

Athenex (ATNX) Receives a Buy from Oppenheimer

In a report released yesterday, Kevin DeGeeter from Oppenheimer maintained a Buy rating on Athenex (ATNX), with a price target of $23.00. The company's

smarteranalyst.com

Atossa Genetics (ATOS) Gets a Buy Rating from Maxim Group

Maxim Group analyst Jason McCarthy assigned a Buy rating to Atossa Genetics (ATOS) today and set a price target of $4.00. The company's shares closed last

smarteranalyst.com

Roche Q1 Sales Call Key Takeaways

We highlight main points from Roche Q1 conference call and summarize key takeaways for investors. Pharma is showing resilience in the face of intensive biosimil

seekingalpha.com

Wall Street Analysts Are Bullish on Top Healthcare Picks

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Selecta Biosciences (SELB), CytoDyn (CYDY) and Sutro

smarteranalyst.com

U.S. RESEARCH ROUNDUP- Arch Coal, Glacier Bancorp, IHS Markit

all Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Arch Coal, Glacier Bancorp and IHS Markit on Monday. HIGHLIGHTS * Arch Coal Inc : Jefferies cuts to hold from buy * Alliance Data Systems Corp : Compass Point raises to buy from neutral * Autoliv Inc : RBC raises to outperform from sector perform * Glacier Bancorp Inc : Piper Sandler raises target price to $33 from $31 * IHS Markit Ltd : RBC raises target price to $84 from $72 Following is a summary of research actions on U.S. companies reported by Reuters on Monday. Stock entries are in alphabetical order. * Adaptimmune Therapeutics Plc : Citigroup cuts price target to $5 from $8 * Adient Plc : Credit Suisse cuts target price to $18 from $30 * Aflac Inc : Credit Suisse cuts target price to $35 from $45 * AIG : Credit Suisse cuts target price to $40 from $51 * Alexander's Inc : Piper Sandler cuts price target to $300 from $340 * Alliance Data Systems Corp : Compass Point cuts price target to $65 * Alliance Data Systems Corp : Compass Point raises to buy from neutral * Amazon.Com Inc : Credit Suisse raises price target to $2800 from $2400 * American Airlines : Citigroup cuts price target to $10 from $13 * American Axle & Manufacturing Holdings Inc : Credit Suisse cuts PT to $4 from $11 * American Axle & Manufacturing Holdings Inc : Credit Suisse cuts to neutral * American Express Co : Compass Point cuts target price to $78 from $140 * American Express Co : Credit Suisse cuts target price to $85 from $90 * American Express Co : Piper Sandler cuts target price to $106 from $119 * Ameris Bancorp : SunTrust Robinson cuts target price to $28 from $30 * Amerisourcebergen Corp : Baird cuts target price to $109 from $112 * Amgen Inc : Oppenheimer raises target price to $250 from $240 * Angi Homeservices Inc : Evercore ISI cuts target price to $6 from $9 * Aon Plc : Piper Sandler cuts price target to $195 from $200 * Apollo Commercial Real Estate Finance Inc : Credit Suisse cuts PT to $7.5 from $18 * Aptiv Plc : Credit Suisse cuts target price to $75 from $96 * Arch Coal Inc : Jefferies cuts target price to $26 from $50 * Arch Coal Inc : Jefferies cuts to hold from buy * Archer Daniels Midland Co : JP Morgan cuts target price to $45 from $48 * Ares Commercial Real Estate Corp : Credit Suisse cuts PT to $9 from $17.5 * Arthur J Gallagher & Co : Piper Sandler cuts price target to $80 from $101 * Athene Holding Ltd : Credit Suisse cuts target price to $46 from $59 * Atlantic Capital Bancshares Inc : SunTrust Robinson cuts PT to $12 from $14 * Autohome Inc : Jefferies cuts target price to $90.60 from $97.30 * Autoliv Inc : Jefferies raises target price to $69 from $61 * Autoliv Inc : RBC raises target price to $74 from $64 * Autoliv Inc : RBC raises to outperform from sector perform * Avalonbay Communities Inc : Evercore ISI raises target price to $185 from $183 * Avangrid Inc : JP Morgan cuts target price to $45 from $49 * Avanos Medical Inc : Keybanc cuts target price to $45 from $48 * BJ's Restaurants Inc : Guggenheim raises target price to $29 from $25 * Blackstone Mortgage Trust Inc : Credit Suisse cuts target price to $24 from $37.5 * Booking Holdings Inc : Evercore ISI cuts target price to $1400 from $1750 * BorgWarner Inc : Credit Suisse cuts target price to $31 from $36 * Boston Properties Inc : Piper Sandler cuts target price to $110 from $155 * Brighthouse Financial Inc : Credit Suisse cuts target price to $34 from $45 * Bunge Ltd : JP Morgan cuts target price to $52 from $59 * Camden Property Trust : Evercore ISI cuts target price to $102 from $103 * Celanese Corp : Jefferies cuts target price to $115 from $140 * Celestica Inc : RBC cuts target price to $5 from $6 * Cheniere Energy Inc : RBC raises target price to $31 from $28 * Cohen & Steers Inc : Evercore ISI raises target price to $57 from $54 * Cohen & Steers Inc : KBW raises target price to $54 from $48 * Core Laboratories NV : RBC raises target price to $15 from $13 * CubeSmart : Evercore ISI cuts target price to $31 from $32 * Curo Group Holdings Corp : Credit Suisse cuts target price to $15 from $19 * CyrusOne Inc : Keybanc raises target price to $75 from $70 * Dana Inc : Credit Suisse cuts target price to $14 from $20 * Delphi Technologies Plc : Credit Suisse cuts target price to $9 from $14 * Delta Air Lines Inc : Citigroup cuts price target to $30 from $33 * Digital Realty Trust Inc : Keybanc raises target price to $155 from $135 * Domino's Pizza Inc : Stephens raises target price to $410 from $350 * Douglas Emmett Inc : Piper Sandler cuts target price to $35 from $50 * EQT Corp : RBC raises target price to $15 from $13 * Equity Residential : Evercore ISI raises target price to $68 from $63 * Extra Space Storage Inc : Evercore ISI cuts target price to $98 from $101 * Fidelity National Financial Inc : Stephens raises target price to $37 from $35 * Freeport-Mcmoran Inc : Credit Suisse raises price target to $9 from $8 * Freeport-Mcmoran Inc : Jefferies raises target price to $15 from $14 * Freeport-Mcmoran Inc : JP Morgan raises target price to $11 from $10 * Glacier Bancorp Inc : KBW raises target price to $37 from $36 * Glacier Bancorp Inc : Piper Sandler raises target price to $33 from $31 * Granite Point Mortgage Trust Inc : Credit Suisse cuts target price to $7 from $18 * Home Depot Inc : Telsey Advisory Group cuts price target to $220 from $244 * Hudson Pacific Properties Inc : Piper Sandler cuts target price to $28 from $42 * IAC/InterActiveCorp : Evercore ISI cuts target price to $285 from $300 * Idex Corp : Citigroup cuts price target to $160 from $165 * Idex Corp : RBC raises target price to $160 from $147 * Idex Corp : Stifel raises target price to $169 from $159 * IHS Markit Ltd : RBC raises target price to $84 from $72 * Interpace Biosciences Inc : Maxim cuts target price to $12 from $20 * Investar Holding Corp : Piper Sandler cuts target price to $13 from $16 * Landstar System Inc : Credit Suisse raises price target to $97 from $92 * Lear Corp : Credit Suisse cuts target price to $120 from $130 * Lear Corp : Credit Suisse raises to outperform from neutral * Life Storage Inc : Evercore ISI cuts target price to $109 from $112 * Lincoln National Corp : Credit Suisse cuts target price to $52 from $68 * Lyft Inc : Evercore ISI cuts target price to $60 from $81 * Magellan Midstream Partners LP : JP Morgan cuts target price to $56 from $57 * Magna International Inc : Credit Suisse cuts target price to $50 from $55 * Magna International Inc : Credit Suisse raises to outperform from neutral * Marsh & Mclennan : Piper Sandler cuts price target to $105 from $124 * Metlife Inc : Credit Suisse cuts target price to $46 from $60 * Midland States Bancorp Inc : Piper Sandler cuts target price to $16.50 from $18 * National Bankshares Inc : Piper Sandler cuts target price to $32 from $37 * National Bankshares Inc : Piper Sandler raises to overweight from neutral * Northern Trust Corp : Citigroup cuts price target to $82 from $85 * Open Text Corp : RBC cuts target price to $45 from $54 * O'Reilly Automotive Inc : Stephens raises target price to $430 from $380 * Peloton Interactive Inc : Evercore ISI raises target price to $35 from $34 * People'S United Financial Inc : KBW cuts target price to $13 from $13.

reuters.com

Interpace Diagnostics Group (NASDAQ:IDXG) Stock Rating Reaffirmed by Maxim Group

Interpace Diagnostics Group (NASDAQ:IDXG)‘s stock had its “buy” rating restated by stock analysts at Maxim Group in a note issued to investors on Friday, AnalystRatings.com reports. They currently have a $12.00 price target on the business services provider’s stock. Maxim Group’s price objective points to a potential upside of 140.00% from the stock’s current price. […]

thelincolnianonline.com

CareDx (CDNA) Receives a Buy from H.C. Wainwright

H.C. Wainwright analyst Yi Chen reiterated a Buy rating on CareDx (CDNA) today and set a price target of $43.00. The company's shares closed last Thursday

smarteranalyst.com

U.S. stocks higher at close of trade; Dow Jones Industrial Average up 1.11%

U.S. stocks higher at close of trade; Dow Jones Industrial Average up 1.11%

investing.com

Analysts Offer Insights on Healthcare Companies: Interpace Diagnostics Group (IDXG) and Principia Biopharma (PRNB)

There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Interpace Diagnostics Group (IDXG) and Principia Biopharma

smarteranalyst.com

Roche décoiffe les attentes au premier trimestre 2020

La croissance a été alimentée par la principale division Pharmaceuticals, dont les revenus ont progressé de 3% à 12,26 milliards. L'action a clôturé en nette hausse.

allnews.ch

Analysts Offer Insights on Healthcare Companies: Rockwell Med (RMTI) and Motus Gi Holdings (MOTS)

There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Rockwell Med (RMTI) and Motus Gi Holdings (MOTS) with

smarteranalyst.com

Coronavirus Scare Supports These Biotech ETFs & Stocks

Stocks Analysis by Zacks Investment Research covering: S&P 500, Dow Jones Industrial Average, Gilead Sciences Inc, Biogen Inc. Read Zacks Investment Research's latest article on Investing.com

investing.com

Hospital Acquired Infections (HAI) Diagnostics Market Trends 2020: Emerging Technologies, Sales Revenue, Key Players Analysis, Development Status, Opportunity Assessment and Industry Expansion Strategies 2023

Mar 18, 2020 (The Expresswire) -- Global “Hospital Acquired Infections (HAI) Diagnostics Market” Report 2020 is a comprehensive, professional report provides...

marketwatch.com

Interpace Diagnostics Group (NASDAQ:IDXG) and LeMaitre Vascular (NASDAQ:LMAT) Head-To-Head Analysis

Interpace Diagnostics Group (NASDAQ:IDXG) and LeMaitre Vascular (NASDAQ:LMAT) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, risk, profitability, earnings and valuation. Volatility and Risk Interpace Diagnostics Group has a beta of 1.74, indicating that its […]

thelincolnianonline.com